바인 테라퓨틱스(VYNE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $42.72 (-0.12%), 시가총액 $0.02B, 52주 범위 $0.29 ~ $1.77.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its
바인 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
바인 테라퓨틱스의 현재 주가는 $42.72 (-0.12%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
바인 테라퓨틱스의 시가총액은 약 $0.02B입니다.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibres